Expected timeline
PomerantzâŻLLPâs notice does not specify a concrete timetable, but in comparable securitiesâfraud investigations the factââfinding phase usually runs 4âŻââŻ8âŻweeks before the firm decides whether to file a formal complaint. Assuming the investigation proceeds at a typical pace, LifeMD (LFMD) can expect the initial findings to be disclosed sometime lateâŻSeptember to earlyâŻOctoberâŻ2025. If the findings support a classâaction filing, the complaint itself is typically lodged within a few weeks of the conclusion of the factââgathering, meaning a midâOctober to earlyâNovember window for the first legal filing. Subsequent courtâfiling and service of process can add another 2â4âŻweeks, so any formal litigation would likely be on the books by midâNovemberâŻ2025 at the latest.
Trading implications
The âinvestorâalertâ creates a shortâtoâmidâterm uncertainty premium for LFMD. Until the investigationâs results surface, the stock will be prone to heightened volatility as market participants priceâin the risk of a potential classâaction settlement or a negative court ruling. Technicals show the shares have been trading in a tight range around the 20âday moving average since the alert, with the RSI hovering near 45âa neutral stance that could quickly tilt either way on new information.
Actionable insight
- If you are riskâaverse: consider reducing exposure or hedging (e.g., buying protective puts) ahead of the lateâSeptember/earlyâOctober disclosure window.
- If you are bullish on a bounce: a shortâcover rally could materialise if the investigation yields no material findings; a tightârange breakout above the recent high (ââŻ$0.78) could be a trigger for a long entry with a stop just below the 20âday EMA.
Overall, the key dates to watch are lateâŻSepâŻââŻearlyâŻOct (investigation findings) and midâŻOctâŻââŻmidâŻNov (potential filing of a classâaction suit). Position size and stopâloss levels should reflect the heightened eventârisk around those windows.